Equity · Healthcare
ABT
NYSEAbbott Laboratories (ABT)
The line runs 110.38 USD on 17 August through 108.53 USD on 13 November, on a scale from 90 to 120. Days the market did not trade hold the previous close, flat.
- Market cap
- 188.0B USD
- P/E (TTM)
- 40.5
- Revenue, year to Dec 2025
- 44.3B USD
- EPS, diluted, year to Dec 2025
- 3.72 USD
- 52-week range
- 83 USD – 131 USD
- Avg volume
- 532.8K
- Mentions, 30 days
- 83
- Net sentiment
- +0.06
as of Nov 13, 2026
Have Abbott Laboratories (ABT) insiders bought or sold shares recently?
In the 90 days to 15 Nov 2026, Abbott Laboratories insiders reported 3 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 7 May 2026.
Form 4, 90 days to 15 Nov 2026, newest reported trade 5 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | Moreland Mary KEXECUTIVE VICE PRESIDENT | Sell | 3,500 | 406K USD |
| 02 Sep 2026 | MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER | Sell | 27 | 3K USD |
| 25 Aug 2026 | Ford Robert BCHAIRMAN AND CEO | Sell | 398,832 | 46.2M USD |
| Sold | 3 open-market sales | 402,359 | $46.61M |
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 23 Sep 2026 | Conroy Kevin TDirector | Tax withheld | 52,507 | 5.5M USD |
| 01 Sep 2026 | MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER | Tax withheld | 52 | 6K USD |
| 01 Sep 2026 | Boudreau Philip PEVP AND CFO | Tax withheld | 388 | 43K USD |
| 25 Aug 2026 | Ford Robert BCHAIRMAN AND CEO | Option exercise | 398,832 | 21.5M USD |
Which funds hold Abbott Laboratories (ABT)?
5 of the 45 institutional funds we track reported a Abbott Laboratories position for the quarter ended 30 Sep 2026 — a combined 142.0M USD; the latest of those filings landed 13 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 467,019 | 46.2M USD | −7.6% |
| Renaissance Technologies | Trimmed | 458,466 | 45.3M USD | −33.2% |
| Marshall Wace | Trimmed | 445,379 | 44.0M USD | −92.0% |
| Soros Fund Management | Held (±25%) | 44,750 | 4.4M USD | |
| GAMCO Investors | Held (±25%) | 21,588 | 2.1M USD | −0.4% |
Have members of Congress traded Abbott Laboratories (ABT)?
The most recent congressional trade disclosed in Abbott Laboratories is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 18 Sep 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 18 Sep 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 24 days |
| 17 Sep 2026 | Thomas H. Kean, Jr.house · Republican–NJ | Sale | 1K USD–15K USD | 43 days |
| 12 Jun 2026 | Richard McCormickhouse · Republican–GA | Purchase | 1K USD–15K USD | 27 days |
| 24 Mar 2026 | Laura Friedmanhouse · Democrat–CA | Exchange | 1K USD–15K USD | 24 days |
| 18 Dec 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 28 days |
| 04 Dec 2025 | Byron Donaldshouse · Republican–FL | Sale | 1K USD–15K USD | 34 days |
| 18 Nov 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 27 days |
| 13 Nov 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 28 days |
What has been filed or recorded for Abbott Laboratories (ABT)?
The filings we hold for Abbott Laboratories, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 15 shares | 2K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 18 shares | 2K USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 789 shares | 78K USD notional · <0.001% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 33 shares | 3K USD notional · <0.001% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 60 shares | 6K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.53 USD | Revenue $13.01B |
| 30 Sep 2026 | Financials | Total assets | 108.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 51.0B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.53 USD | Revenue $12.59B |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.61 USD | Revenue $11.16B |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 3.72 USD | Revenue $44.33B |
| 31 Dec 2025 | Financials | Revenue | 44.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 6.5B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 3.72 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.94 USD | Revenue $11.37B |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 1.01 USD | Revenue $11.14B |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.76 USD | Revenue $10.36B |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 7.64 USD | Revenue $41.95B |
What is Reddit saying about Abbott Laboratories (ABT)?
Reddit mentioned ABT 83 times in the 30 days to 14 November 2026, across 7 of the communities we track. All of them were scored for sentiment: 58% read bullish, 13% bearish and 29% neither. Reddit data updated 14 November 2026.
30-day window, Method
How do Reddit mentions of Abbott Laboratories (ABT) compare with its price?
Share ↗
Is the Reddit crowd more bullish on Abbott Laboratories than on the market?
ABT reads 71% bullish, 20 points above the market (51%). Over 90 days the gap has run from -25 to +25 points.
- ABT
- 71%
- bullish, 14 Nov
- Market
- 51%
- bullish, all Reddit, 14 Nov
- Gap
- +20 pts
- ABT against market
Which subreddits are talking about Abbott Laboratories (ABT)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 84% | 70 | +0.06 |
| r/commodities | 4% | 3 | +0.10 |
| r/ausfinance | 2% | 2 | +0.08 |
| r/cryptocurrency | 2% | 2 | +0.10 |
| r/investing | 2% | 2 | +0.09 |
| r/etfs | 2% | 2 | −0.17 |
| r/stocks | 2% | 2 | +0.05 |
Which names move with Abbott Laboratories (ABT) on Reddit?
FWD moved most closely with Abbott Laboratories (ABT): when the crowd talked about one, it talked about the other (+0.80 over 31 days). Co-discussion, not price.
ABT | +0.80 | +0.78 | +0.75 | +0.73 | +0.70 | +0.70 |
|---|
View the matrix as a tableHide the table
| Pair | Match | Days measured |
|---|---|---|
| ABT and FWD | +0.80 | 31 days |
| ABT and REKT | +0.78 | 31 days |
| ABT and ET | +0.75 | 31 days |
| ABT and IQ | +0.73 | 31 days |
| ABT and STG | +0.70 | 31 days |
| ABT and WAT | +0.70 | 31 days |
What do people ask about Abbott Laboratories (ABT)?
What did Abbott Laboratories shares close at?108.53
Abbott Laboratories closed at 108.53 USD on 13 Nov 2026, up 1.17% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Abbott Laboratories’ market cap?188.0B
Abbott Laboratories is worth 188.0B USD by market value as of 13 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Abbott Laboratories’ P/E ratio?40.5
Abbott Laboratories has a price-to-earnings ratio of 40.5, as of 13 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Abbott Laboratories’ revenue?44.3B
Abbott Laboratories reported revenue of 44.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Abbott Laboratories insiders bought or sold shares recently?3 sales
In the 90 days to 15 Nov 2026, Abbott Laboratories insiders reported 3 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 7 May 2026. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Abbott Laboratories?5 of 45
5 of the 45 funds we track reported a Abbott Laboratories position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Fisher Asset Management, Renaissance Technologies and Marshall Wace. See Funds
Have members of Congress traded Abbott Laboratories?50 trades
Yes. 50 trades in Abbott Laboratories appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 18 Sep 2026, filed 12 Oct 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Abbott Laboratories last report earnings?0.53
Abbott Laboratories last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.53 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Abbott Laboratories?7 mentions
Abbott Laboratories was mentioned 7 times in the last 7 days across the finance subreddits we track, and 83 times over the trailing 30 days. Of the 83 mentions scored for sentiment, 58% read bullish and 13% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Byron Donalds: United States Congress, Public domain; Thomas H. Kean, Jr.: Office of Congressman Tom Kean, Public domain; Laura Friedman: California State Assembly, Public domain; Richard McCormick: United States Congress, Public domain; Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings